Eli Lilly / J2j-MC-JZLH / EMBER-4

Official Title

A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence

Study Purpose

This study is being done to see how safe an investigational drug is and how well it will work to help people with Estrogen receptor positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), early breast cancer with an increased risk of recurrence. 

Diagnosis

Estrogen receptor positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), early breast cancer with an increased risk of recurrence.

Eligibility

Male or Female Estrogen receptor positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), early breast cancer with an increased risk of recurrence. 

 

Intervention

Imlunestrant vs Standard Adjuvant Endocrine Therapy